Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19264160 | 0.91 | PDE5A (0.69) | PDE5A | |
| SCHEMBL15990880 | 0.91 | PDE5A (0.57) | PDE5A | |
| SCHEMBL15937483 | 0.90 | PDE5A (0.65) | PDE5A | |
| SCHEMBL14488371 | 0.90 | PDE5A (0.68) | PDE5A | |
| SCHEMBL17541916 | 0.89 | PDE5A (0.59) | PDE5A | |
| SCHEMBL17541164 | 0.89 | PDE5A (0.64) | PDE5A | |
| SCHEMBL326432 | 0.89 | PDE5A (0.79) | PDE5A | |
| SCHEMBL17541225 | 0.88 | PDE5A (0.63) | PDE5A | |
| SCHEMBL14746677 | 0.88 | PDE5A (0.71) | PDE5A | |
| SCHEMBL17541316 | 0.88 | PDE5A (0.64) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751106-B1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER IP GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| EP-2751106-B1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER IP GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| EP-2729476-B1 | HETEROARYL SUBSTITUTED PYRAZOLOPYRIDINES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2729476-B1 | HETEROARYL SUBSTITUTED PYRAZOLOPYRIDINES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | disclosed |
| EP-3186255-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030354-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-03 | — | — | WO | disclosed |
| US-20150105374-A1 | Substituted annellated pyrimidines and use thereof | BAYER IP GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105374-A1 | Substituted annellated pyrimidines and use thereof | BAYER IP GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| US-8859569-B2 | Substituted annellated pyrimidines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859569-B2 | Substituted annellated pyrimidines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20140228366-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228366-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| EP-2751106-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013030288-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | TYMP, TYMS, DPYD | PDE5A 1769/4885 |
| US-20150105374-A1 | Substituted annellated pyrimidines and use thereof | TYMS, TYMP, NUDT1 | PDE5A 1606/4885 |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | TYMP, DPYD, TYMS | PDE5A 1936/4885 |
| US-20140228366-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B2, GUCY1B1 | PDE5A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.